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Abstract
Many studies have been conducted to try and find interventions to
treat patients with severe sepsis, but with little success. In several
cases, initial apparent beneficial effects have not been confirmed in
later trials. The story of steroids in sepsis is one example of this
pendulum effect, with initial success in the study by Annane et al.
tempered by the more recent negative results of the Corticus
study. The reasons for this pendulum effect are likely related, at
least in part, to issues of clinical trial design and the way in which
clinical trials in intensive care unit patients are developed,
conducted and assessed needs to be critically reassessed.
The search for effective interventions in sepsis has, in several
cases, been associated with rather inconsistent results from
clinical studies, as the pendulum seems to swing from a
benefit effect through no effect to potential harm and all the
way back to benefit, leaving the practicing clinician with a real
therapeutic dilemma. This pendulum in clinical trial results is
demonstrated well by the use of steroids in the treatment of
patients with sepsis.
Forty years ago, high-dose steroids were used in the belief
that, because sepsis is an inflammatory response, the anti-
inflammatory properties of steroids could be useful. Initial
studies were encouraging, with Schumer demonstrating that
treatment with one or two doses of intravenous dexametha-
sone (3 mg/kg) or methylprednisolone (30 mg/kg) was
associated with reduced mortality compared with saline
treatment in patients with septic shock [1]. Two large,
double-blind, randomized controlled trials later failed to
confirm these findings [2,3], however, and two meta-analyses
in the mid 1990s concluded that steroids were ineffective [4]
or indeed were potentially harmful [5] in sepsis.
Then, in the late 1990s, several studies were published
suggesting a role for much smaller, so-called stress, doses of
steroids in reducing vasopressor requirements in patients
with septic shock [6-8]. These results led to a study by
Annane and colleagues in which patients with relative adrenal
insufficiency – as assessed by nonresponse to a cortico-
tropin test – who were treated with hydrocortisone (50 mg
intravenously every 6 hours) and fludrocortisone (50 μg orally
daily) for 7 days had a reduced mortality compared with
nonresponders treated with placebo [9]. Despite concerns
regarding the lack of statistical significance in overall mortality
rates at 28 days, the results from this study led to steroids
being recommended in the treatment of patients with septic
shock [10]. Steroid use was also incorporated into the so-
called sepsis bundles, with the recommendation that all
patients with septic shock should receive low-dose cortico-
steroids within 24 hours of diagnosis.
Doubts remained, however, and a large, international,
multicenter study was conducted to confirm the results of the
earlier study [9]. The Corticus – Corticosteroid Therapy of
Septic Shock – study, which included close to 500 patients,
recently showed that hydrocortisone did not improve survival
or reversal of shock in patients with septic shock, either
overall or in patients who did not respond to a corticotropin
test [11]. The results from the Corticus study were somewhat
disappointing, and, in the accompanying editorial, Dr Finfer
suggested the need for a further study to explore the effects
of steroids in septic shock in a much larger population [12].
With no signal from the Corticus study, however, merely
increasing the size of the study is unlikely to show mortality
differences.
Importantly, apart from the differences in effects on outcome,
there were other notable differences between the Corticus
study [11] and Annane and colleagues’ study [9], including
the larger number of postoperative patients, the more
common abdominal source of the sepsis, and, in particular,
the lower severity of illness in the Corticus study. This latter
factor is particularly important and can be explained by the
fact that many patients with severe septic shock were treated
with steroids in accordance with guidelines current at the
time of the study [10], and hence were excluded from
enrollment – so the included population, by definition,
consisted of less severely ill patients. As a result of this lower
Commentary
Steroids in sepsis: another swing of the pendulum in 
our clinical trials
Jean-Louis Vincent
Department of Intensive Care, Université libre de Bruxelles, Erasme Hospital, route de Lennik 808, 1070 Brussels, Belgium
Corresponding author: Jean-Louis Vincent, jlvincen@ulb.ac.be
Published: 29 April 2008 Critical Care 2008, 12:141 (doi:10.1186/cc6861)
This article is online at http://ccforum.com/content/12/2/141
© 2008 BioMed Central LtdPage 2 of 2
(page number not for citation purposes)
Critical Care    Vol 12 No 2 Vincent
severity of illness, the mortality rate in the Corticus study was
about one-half that of Annane and colleagues’ study. It is
therefore still possible that steroids may decrease mortality in
very ill patients, just not in those with moderately severe shock.
Similar observations were made with activated protein C,
another adjunct therapy for sepsis, which was shown to
reduce mortality in very ill patients [13] but not in those
patients with a lower risk of death [14]. I believe we do need
another trial of steroids in sepsis, but specifically in patients
with severe septic shock rather than just in a larger general
population of septic shock patients.
In this age of evidence-based medicine, we urgently need
well-designed, appropriately targeted clinical trials to provide
convincing and reliable data on which we can base future
guidelines and recommendations for the treatment of patients
with septic shock. Importantly there can be no ideal global
clinical trial model – the design of each clinical trial must be
adapted according to the question it is attempting to answer;
however, general principles of clinical trial design can be
developed. To this end, a round table held in March 2008
joined 26 leaders in critical care medicine to create a think-
tank on the subject of improving clinical trials in the critically
ill. Participants presented, discussed, and debated all
aspects of clinical trial conduct, including inclusion and
exclusion criteria, sample sizes, timing, ethical issues,
selection of endpoints, power calculations, the benefits of
multicenter studies over single-center studies, logistics, and
much more.
There is no doubt there is an urgent need to improve
outcomes for patients with sepsis, but – in our rush to
produce that all-powerful randomized controlled trial – details
of clinical trial design can be overlooked, making the end
result less than ideal. Perhaps the time has come to take a
step back and reflect on past efforts so that future clinical
trials will be conducted in an optimal manner to limit the
pendulum effect and to provide results that stand up to
scrutiny and can be immediately introduced into clinical
practice to the benefit of our patients.
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